(Q38006504)

26 August 2017

Update on incretin hormones (English)

1 reference

26 August 2017

Liza K Phillips

1

1 reference

PubMed ID

22545749

26 August 2017

Johannes B Prins

series ordinal

2

1 reference

PubMed ID

22545749

26 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Annals of the New York Academy of Sciences

26 August 2017

1 reference

26 August 2017

1243

1 reference

26 August 2017

E55-74

1 reference

Biology of incretins: GLP-1 and GIP

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

What do we know about the secretion and degradation of incretin hormones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Incretin hormone secretion over the day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Snapin mediates incretin action and augments glucose-dependent insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Neuroprotective properties of GLP-1: theoretical and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gut peptides in the control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Impact of glucose-dependent insulinotropic peptide on age-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Role of gastrointestinal hormones in postprandial reduction of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Functional GIP receptors are present on adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide therapy in insulin-treated type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide (exendin-4)-induced pancreatitis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1-based therapies: the dilemma of uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Incretin-based therapies: review of current clinical trial data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Impact of sitagliptin on markers of beta-cell function: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Thiazolidinediones: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06491.X

10.1111/J.1749-6632.2012.06491.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22545749